Physician profile
Wallace J Wang
NPI 1598924805
$134,855.26
in general payments reported to CMS, 2019-2025
25 companies · $19K in 2025
The $19K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,640 · 2020: $21K · 2021: $26K · 2022: $27K · 2023: $15K · 2024: $24K · 2025: $19K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $47K · Food and Beverage: $6,221 · Travel and Lodging: $4,415 · Consulting Fee: $1,270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $46,570.00 |
| Food and Beverage | $6,221.11 |
| Travel and Lodging | $4,414.61 |
| Consulting Fee | $1,270.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $126,135.55 | 2019-2025 | Vemlidy |
| Abbvie INC. | $3,118.36 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Ardelyx, INC. | $1,091.61 | 2022-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $777.44 | 2024-2025 | Rezdiffra, Resmetirom |
| Allergan, INC. | $537.05 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $492.09 | 2020-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $490.24 | 2021-2025 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $423.37 | 2024-2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $387.87 | 2023 | Zeposia |
| Amarin Pharma, INC. | $235.04 | 2019 | |
| Intercept Pharmaceuticals, INC. | $189.63 | 2020-2023 | Ocaliva |
| Ironwood Pharmaceuticals, INC | $178.21 | 2019-2022 | |
| Fujifilm Healthcare Americas Corporation | $141.17 | 2021 | |
| Sirtex Medical INC | $134.48 | 2023 | Sir-Spheres Microspheres |
| Medtronic, INC. | $110.96 | 2025 | Interstim |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $96.38 | 2019 | |
| Redhill Biopharma INC. | $80.00 | 2020-2021 | |
| Celgene Corporation | $71.89 | 2023 | Zeposia |
| Intra-Sana Laboratories | $36.05 | 2021-2022 | |
| Janssen Biotech, INC. | $24.47 | 2024 | Stelara |
| Vivus LLC | $22.52 | 2024 | Pancreaze |
| Aimmune Therapeutics, INC. | $21.25 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $20.37 | 2021 | |
| Boston Scientific Corporation | $20.37 | 2019 | |
| Concordia Pharmaceuticals INC. | $18.89 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wallace Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.